PUFAs in Preterm Infants

Launched by THE FIRST HOSPITAL OF JILIN UNIVERSITY · Sep 13, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the role of Polyunsaturated Fatty Acids (PUFAs) in premature infants, particularly those born between 24 and 36 weeks of pregnancy. PUFAs are important fats that may help prevent serious health issues like necrotizing enterocolitis (a severe intestinal condition), brain bleeding, lung problems, and infections. The researchers want to understand how these fats work in the bodies of premature infants and how they might help reduce the risk of these diseases.

To participate in the trial, infants must be admitted to the hospital within 24 hours of birth. However, babies with serious birth defects or those who need extra PUFA supplements beyond what's typically given won't be included. The study is not yet recruiting participants, but once it starts, parents can expect their babies to be monitored closely to see how PUFAs affect their health. Ultimately, this research aims to provide valuable information that could lead to better care and outcomes for premature infants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Infants born between 24 and 36 weeks of gestational age who are admitted within 24 hours of birth, including both premature and full-term newborns.
• • -
• Exclusion Criteria:
• • Infants with severe congenital developmental abnormalities, those requiring external supplementation of PUFAs in addition to standard intravenous nutrition and breastfeeding, and those with a severe prognosis indicating non-survival during their hospitalization.
• • -